Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 2/20 | 0.57 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12346711 | 0.94 | NAMPT (0.56) | RAB9ANAMPTCYP17A1L3MBTL1NR1H4 | |
| SCHEMBL506891 | 0.91 | CYP17A1 (0.61) | RAB9ANAMPTCYP17A1L3MBTL1NR1H4 | |
| SCHEMBL5459163 | 0.90 | CYP17A1 (0.57) | RAB9ANAMPTCYP17A1L3MBTL1NR1H4 | |
| SCHEMBL3180689 | 0.88 | L3MBTL1 (0.61) | NAMPTL3MBTL1GAAMAPT | |
| SCHEMBL5479565 | 0.86 | CYP17A1 (0.50) | RAB9ANAMPTCYP17A1L3MBTL1NR1H4 | |
| SCHEMBL2024124 | 0.84 | CYP17A1 (0.53) | RAB9ANAMPTCYP17A1HTTCYP3A4 | |
| SCHEMBL17963188 | 0.84 | CYP17A1 (0.53) | RAB9ANAMPTCYP17A1L3MBTL1NR1H4 | |
| SCHEMBL1438618 | 0.84 | NAMPT (0.75) | NAMPTCYP17A1L3MBTL1LMNAMAPT | |
| SCHEMBL3838871 | 0.83 | CA12 (0.63) | RAB9ANAMPTL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL16630327 | 0.83 | NAMPT (0.51) | RAB9ANAMPTCYP17A1L3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109192517-A | A kind of quasi-solid electrolyte and preparation method thereof based on cogelled dose of multicomponent is applied with it | 中国科学院合肥物质科学研究院 | 2019-01-11 | — | — | CN | claimed |
| CN-103779092-A | Multicomponent supramolecular gel electrolyte, preparation method and application thereof | INST PLASMA PHYSICS CAS | 2014-05-07 | — | — | CN | claimed |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025045758-A1 | ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF | MABLINK BIOSCIENCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025045761-A1 | MOLECULAR GLUE DEGRADERS AND USES THEREOF | MABLINK BIOSCIENCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| EP-4512806-A1 | MOLECULAR GLUE DEGRADERS AND USES THEREOF | Mablink Bioscience (FR) | 2025-02-26 | — | — | EP | disclosed |
| EP-4512427-A1 | ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF | Mablink Bioscience (FR) | 2025-02-26 | — | — | EP | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-5705487-A | PEPTIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| CN-1147205-A | antithrombotic agent | LILLY CO ELI (US) | 1997-04-09 | — | — | CN | disclosed |
| US-5602253-A | STARTING MATERIAL FOR SERINE PROTEASE INHIBITORS | AKTIEBOLAGET ASTRA (SE) | 1997-02-11 | — | — | US | disclosed |
| CN-1127509-A | Novel peptide derivatives | ASTRA AB (SE) | 1996-07-24 | — | — | CN | disclosed |
| EP-0701568-A1 | NEW PEPTIDE DERIVATIVES | Astra Aktiebolag (SE) | 1996-03-20 | — | — | EP | disclosed |
| EP-0672658-A1 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995023609-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1994029336-A1 | NEW PEPTIDE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1994-12-22 | — | — | WO | disclosed |
| EP-0609625-A1 | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1994-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | RAB9A 4270/4885NAMPT 1694/4885CYP17A1 1927/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | RAB9A 1632/4885NAMPT 3339/4885CYP17A1 968/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | RAB9A 4270/4885NAMPT 1694/4885CYP17A1 1927/4885 |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | RAB9A 1971/4885NAMPT 4217/4885CYP17A1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.